Payment overview · 2025
General Payments
$3,825.14
72 reported records · 25 companies
Healthcare provider profile · identity verified
Gautum Agarwal, MD
Allopathic & Osteopathic Physicians|Urology · SAINT LOUIS, MO · NPI 1780880633
Verified facts
What the public records show
CMS Open Payments records show Gautum Agarwal, MD received $3,825.14 in general payments during 2025 across 72 reported records.
Janssen Biotech, Inc. accounted for 68.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $2,620.06 | 68.5% | 9 | 2025 |
| COLOPLAST CORP | Unresolved — no canonical attribution shown | $200.23 | 5.2% | 26 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $171.10 | 4.5% | 2 | 2025 |
| Calyxo, Inc. | Unresolved — no canonical attribution shown | $116.01 | 3.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $80.26 | 2.1% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $61.35 | 1.6% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $57.47 | 1.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.92 | 1.4% | 3 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.68 | 1.3% | 2 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $44.07 | 1.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $43.22 | 1.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.75 | 0.9% | 2 | 2025 |
| UROGEN PHARMA, INC. | Unresolved — no canonical attribution shown | $32.66 | 0.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $29.97 | 0.8% | 1 | 2025 |
| ABC Home Medical Supply, Inc. | Unresolved — no canonical attribution shown | $29.19 | 0.8% | 2 | 2025 |
| Olympus America Inc. | Unresolved — no canonical attribution shown | $27.47 | 0.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.58 | 0.6% | 1 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $22.46 | 0.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.20 | 0.6% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.67 | 0.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.06 | 0.5% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $18.20 | 0.5% | 1 | 2025 |
| pharmaand GmbH | Unresolved — no canonical attribution shown | $18.20 | 0.5% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $15.52 | 0.4% | 1 | 2025 |
| KARL STORZ Endoscopy-America | Unresolved — no canonical attribution shown | $14.84 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $2,340.00 | 1 |
| Food and Beverage | $1,214.05 | 68 |
| Travel and Lodging | $171.10 | 2 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $177.10 | 5 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $171.10 | 2 | 2025 |
Source payment records
|
|||||
| CVAC ASPIRATION SYSTEM Normalized: cvac aspiration system |
Device | Calyxo, Inc. | $116.01 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological, Drug | Astellas Pharma US Inc, PFIZER INC. | $98.14 | 5 | 2025 |
Source payment records
|
|||||
| Luja Coude Normalized: luja coude |
Device | COLOPLAST CORP | $95.10 | 16 | 2025 |
Source payment records
|
|||||
| SpeediCath Normalized: speedicath |
Device | COLOPLAST CORP | $85.68 | 9 | 2025 |
Source payment records
|
|||||
| General - Kidney Stone Disease Normalized: general kidney stone disease |
Device | Boston Scientific Corporation | $59.35 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $57.47 | 3 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $57.47 | 3 | 2025 |
Source payment records
|
|||||
| ADSTILADRIN Normalized: adstiladrin |
Biological | Ferring Pharmaceuticals Inc. | $49.68 | 2 | 2025 |
Source payment records
|
|||||
| Tivdak Normalized: tivdak |
Drug | Genmab U.S., Inc. | $44.07 | 2 | 2025 |
Source payment records
|
|||||
| RUBRACA Normalized: rubraca |
Drug | TOLMAR, INC., pharmaand GmbH | $36.40 | 2 | 2025 |
Source payment records
|
|||||
| LUPRON DEPOT Normalized: lupron depot |
Drug | ABBVIE INC. | $32.75 | 2 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $29.97 | 1 | 2025 |
Source payment records
|
|||||
| iTIND System Normalized: itind system |
Device | Olympus America Inc. | $27.47 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| ZENITH SPIRAL-Z Normalized: zenith spiral z |
Device | Cook Medical LLC | $22.46 | 2 | 2025 |
Source payment records
|
|||||
| LUMAKRAS Normalized: lumakras |
Drug | Amgen Inc. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| VECTIBIX Normalized: vectibix |
Biological | Amgen Inc. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| SpaceOAR VUE System - 10mL Normalized: spaceoar vue system 10ml |
Device | Boston Scientific Corporation | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| Trelstar Normalized: trelstar |
Drug | Verity Pharmaceuticals Inc. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| SenSura Mio Normalized: sensura mio |
Device | COLOPLAST CORP | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| ELIGARD Normalized: eligard |
Drug | TOLMAR, INC. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| GENTLECATH GLIDE Normalized: gentlecath glide |
Device | ConvaTec Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| n.a. Normalized: n a |
Device | KARL STORZ Endoscopy-America | $14.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tamsulosin Hcl | Tamsulosin Hcl | 266 | 78 |
| Finasteride | Finasteride | 231 | 64 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 108 | 93 |
| Cefuroxime | Cefuroxime Axetil | 52 | 48 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,825.14 · 72 records | Janssen Biotech, Inc. | ADSTILADRIN, CVAC ASPIRATION SYSTEM, Da Vinci Surgical System, ELIGARD, ERLEADA, GENTLECATH GLIDE, General - Kidney Stone Disease, INLYTA, KEYTRUDA, KEYTRUDA QLEX, LUMAKRAS, LUPRON DEPOT, Lenvima, Luja Coude, Nubeqa, OPDIVO, PADCEV, RUBRACA, SenSura Mio, SpaceOAR VUE System - 10mL, SpeediCath, Tivdak, Trelstar, VECTIBIX, WELIREG, ZENITH SPIRAL-Z, iTIND System, n.a. | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error